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Introduction
Typical pathological events in Asthma include bronchial inflammation, airway hyperresponsiveness and airflow obstruction. Allergic asthma makes up most asthma cases, characterized by activation of type-2 T helper cells, IgE production, eosinophilia, and an inappropriate T cell response to environmental allergens [1] [2] [3] [4] .
Regulatory T cells (Treg) are T cells that suppress potentially harmful immune responses, and have been shown to suppress inflammatory responses and airway hyper-responsiveness to maintain peripheral immune tolerance [5] [6] [7] . Treg has been defined by surface markers of combined CD4 and CD25 and also characterized by expression of a member of the forkhead box transcription factor, Foxp3 [7] [8] [9] . Foxp3 is crucial for naive T cell differentiation towards the Treg phenotype and its expansion [7] [8] [9] [10] [11] [12] [13] [14] . However, the molecular bases underlying the activation of Treg through Foxp3 are not completely understood.
Previous studies have shown that herb-drug could improve the therapeutic effects and reduce side effects during cancer treatment. Saffron is a Chinese traditional herb, and Crocetin is the major constituent of saffron, which has recently found to have multiple pharmacological effects including anticancer [15] [16] [17] . However, the effects of Crocetin on asthma as well as the underlying mechanisms have not been studied.
Tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 (TIPE2) was first identified as a novel immune negative molecule that regulates the adaptive and innate immunity [18, 19] . TIPE2 was later found to inhibit inducible nitric oxide synthase (iNOS) and thus generation of nitric oxide, resulting in suppression of inflammation [20] [21] [22] [23] [24] [25] [26] [27] . The dysregulation of TIPE2 has also been found to mediate diverse immunological diseases [28] [29] [30] [31] [32] . However, whether TIPE2 may be involved in the pathogenesis of asthma and regulation of Treg has not been reported.
In the current study, we studied the effects of Crocetin treatment on the severity of an ovalbumin (OVA)-induced asthma in mice, and in this model, we studied the relationship between TIPE2 and Foxp3 in Treg cells.
Materials and Methods

Mouse handling
All mouse experiments were approved by the IACUC of Shanghai Pulmonary Hospital. Only 10-weekold male C57BL/6 mice (Jackson lab, Bar Harbor, ME, USA) were used for in vivo experiments. Mice were housed in a specific pathogen-free environment.
Ovalbumin (OVA)-induced allergic asthma model and Crocetin treatment
Male C57BL/6 mice of 10 weeks of age were sensitized with an intraperitoneal injection of 50 μg OVA (OVA, grade V; Sigma-Aldrich, St. Louis, MO, USA) with 2 mg aluminum hydroxide gel (Alum; SigmaAldrich) once per week for 3 times (week 0-2). Then the mice were challenged with 50 μg OVA by intranasal administration under light anesthesia every other day for another 7 weeks (week 3-9). Control mice received PBS. After another week, the mice were examined, sampled and analyzed (week 10). Crocetin (C 20 H 24 O 4 , molecular weight, 328.4, MP Biomedicals, Santa Ana, CA, USA) in 100 µl dimethyl sulfoxide (DMSO) was given by intranasal administration after OVA challenge daily at a dose of 100 µmol/l till the end of the experiment (week 9-10).
Airway hyper-responsiveness
Airway hyper-responsiveness (AHR) was measured by restrained invasive plethysmography 1 day after the last intranasal OVA challenge. Mice were anesthetized, after which a small incision was made to expose the trachea, and a cannula was inserted to connect to an inline nebulizer and ventilator. Mice were then challenged with aerosolized PBS followed by increasing doses of methacholine (Sigma-Aldrich). Airway resistance and dynamic compliance (Cdyn) were determined by analysis of pressure and flow waveforms.
Bronchoalveolar lavage, lung digestion and isolation of Treg
Mice were euthanized by pentobarbitone overdose after AHR examination. Bronchoalveolar lavage fluid (BALF) was obtained by instilling three washes of 0.4ml PBS with 0.1% BSA. BALF was centrifuged at 470g for 5 min, and cells were enumerated and labeled for further analysis. For lung digestion, lungs were perfused with PBS, after which 0.8 ml 300 U/ml collagenase type I (Sigma-Aldrich), and 50 U/ml DNase I (Roche, Nutley, NJ, USA) in RPMI 1640 was injected into the trachea. Lungs were then removed, minced into small pieces, and digested at 37°C for 30 min. Lung pieces were disrupted with a syringe plunger, filtered through nylon mesh, and centrifuged. The cell pellet was resuspended in RBC lysis buffer, washed, enumerated, and labeled for flow cytometric analysis. Treg was analyzed and purified by fluorescenceactivated cell sorting (FACS) with specific fluorescence-conjugated antibodies (CD4 and CD25, all from Becton-Dickinson Biosciences, San Jose, CA, USA) on a FACSAria cell sorter (Becton-Dickinson Biosciences). Data were analyzed using Flowjo software (Flowjo LLC, Ashland, OR, USA).
Lentivirus production and in vitro and in vivo transduction
We used a pcDNA3.1-CAG-GFP plasmid as backbones (all from Clontech, Mountain View, CA, USA). The sequence for shTIPE2 is 5'-CCG TGT AAA CCA CTC AAC TCA TCTT-3', and the sequence for shFoxp3 is 5'-GCA CAT TCC CAG AGT TCCT-3'. The plasmids and target shRNA (or control scrambled sequence-scr) were digested with Xhol and BamHI and subcloned with a 2A into a pcDNA3.1-CAG-luciferase, resulting in a construct named pCAG-shTIPE2-2A-GFP or pCAG-shFoxp3-2A-GFP. The small 2A peptide sequences, when cloned between genes, allow for efficient, stoichiometric production of discrete protein products within a single vector through a novel "cleavage" event within the 2A peptide sequence. Sequencing was performed to confirm the correct orientation of the new plasmid. To generate lentiviral particles, HEK293T cells were seeded in a 100 mm dish at 50,000 cells/cm 2 and co-transfected with 10 µg of target plasmids and 5 µg each of packaging plasmids (REV, pMDL and VSV-G) using Lipofectamine-2000 (Invitrogen). The supernatant containing lentiviral particles was collected 48 hours after transfection and filtered through a 0.45 µm syringe filter. The viruses were purified using CsCl density centrifugation and then titered by a quantitative densitometric dot-blot assay. For cell transduction in vitro, Treg were seeded in 100mm plates at 15,000 cells/cm 2 one day prior to lentiviral infection. The lentiviral particles were added along with 10 µg/ml polybrene (Sigma-Aldrich) to the cell culture at a multiplicity of infection (MOI) of 100 for 48 hours. Then the cells were washed twice with complete media and the transduction efficiency (> 90%) was evaluated by GFP. For in vivo transduction, the 10 6 virus was injected via tail vein.
RT-qPCR
Total RNA was extracted from purified Treg by FACS or mouse lung, using RNeasy (Qiagen, Hilden, Germany), and cDNA synthesis was performed by reserve transcription. Quantitative PCR (RT-qPCR) was performed in duplicates with QuantiTect SYBR Green PCR Kit (Qiagen). All primers were purchased from Qiagen. Data were collected and analyzed using 2 -△△Ct method for quantification of the relative mRNA expression levels. Values of genes were first normalized against β-actin, and then compared to experimental controls.
Statistics
Statistical analysis was performed with the unpaired two-tailed Student t test (for comparison between two groups), one-way ANOVA with the Tukey posttest (for comparison between three or more groups), or repeated-measures ANOVA with the Dunnett posttest (for AHR dose-response curves), using GraphPad Prism software (GraphPad Software, Inc. La Jolla, CA, USA). Data were represented as mean ± SD and were considered significant if p < 0.05.
Results
Crocetin attenuates OVA-induced hallmarks of the asthma
We used OVA-induced mouse asthma model in our study. In this model, mice were first sensitized to alum-adsorbed OVA for 2 weeks, and then exposed to repeated airway provocation for 7 weeks to develop AHR. Crocetin was given after OVA challenge for one week, and then the mice were analyzed (Fig. 1A) . The establishment of asthma model was demonstrated by a dose-dependent increase in lung resistance (Rl) and decrease in Cdyn in response to a cholinergic stimulus (methacholine), which were significantly attenuated by Crocetin treatment (Fig. 1B-C) . Another hallmark feature of OVA-induced allergic asthma 
Crocetin increases Treg cells in OVA-treated mouse lung
Then we aimed to find out the molecular mechanisms underlying the therapeutic effects of Crocetin. We hypothesized that Treg cells may be regulated by Crocetin, since Treg cells are potent inflammation suppressor in asthma. We used CD4 and CD25 to purify Treg from the lung digests of the mice by flow cytometry (Fig. 2A) . We found that OVA itself did not significantly increase Treg, but we detected a significant increase in Treg cell number in the Crocetin-treated mouse lung (Fig. 2B) . Interestingly, we found that the levels of both Foxp3 and TIPE2 significantly increased in CD4+CD25+ Treg cells from OVA+Crocetin treated mouse lung, compared to control or OVA-only-treated mice (Fig. 2C) . Thus, Crocetin increases Treg in OVA-treated mouse lung, and the levels of Foxp3 and TIPE2 in Treg.
Depletion of Foxp3 abolishes the effects of Crocetin on OVA-asthma without affecting TIPE2
In order to examine the role of Foxp3 and TIPE2 in Crocetin-treated OVA-asthma, we generated a lentivirus carrying shFoxp3 or a scrambled sequence control (scr). These viruses were first used to transduce primary mouse CD4+CD25+ Treg in vitro. First, the knock-down of Foxp3 in Treg by shFoxp3 was confirmed by RT-qPCR (Fig. 3A) . We found that depletion of Foxp3 in Treg did not alter TIPE2 levels (Fig. 3B) . Then, these viruses were given to mice at 9 week, immediately before Crocetin treatment (Fig. 3C) . We found that depletion of Foxp3 by lentivirus abolished the increases in Treg by Crocetin (Fig. 3D-E) , resulting in abolishment of the effects of Crocetin on RI (Fig. 3F) , and Cdyn (Fig. 3G) . These data suggest that depletion of Foxp3 abolishes the effects of Crocetin on OVA-asthma and Treg, without affecting TIPE2. 
Discussion
Crocetin is a sort of carotenoids that have been reported of a lot of biomedical properties including anticancer [33, 34] . Nevertheless, its regulation on inflammatory responses has not been extensively studied. Especially, a role of Crocetin in asthma treatment is not acknowledged. Here, we sought to determine the role of Crocetin in asthma control, as well as the critical cellular and molecular signaling that mediate the activation of Treg cells by Crocetin to alleviate allergic asthma.
TIPE2 is a recently detected molecular with anti-inflammatory potential. TIPE2 is an essential negative regulator of inflammation and immune homeostasis. TIPE2-deficent mice suffer from chronic inflammatory diseases and TIPE2-deficient T cells and macrophages produce significantly increased levels of inflammatory cytokines. The inflammatory disease in TIPE2-deficent mice shares many similarities with those that have Foxp3 deficiency [35] . Thus, a regulatory relationship between TIPE2 and Foxp3, although never examined, deserves exploration.
We used a well-established mouse allergic asthma model [23] , and purified CD4+CD25+ Treg. First, we showed that Crocetin attenuated OVA-induced hallmarks of the asthma. Next, we found that the number of Treg was increased by Crocetin. Since Foxp3 is a regulator of Treg activation and amplification, we examined the levels of Foxp3 in Treg, and found that Foxp3 was significantly increased by Crocetin. Moreover, we also examined the levels of TIPE2 in Treg, and found that it similarly upregulated after Crocetin treatment. Hence, we thought that both TIPE2 and Foxp3 may be involved in the effects of Crocetin on Treg. To prove it, we knocked out either TIPE2 or Foxp3 in Treg, and found that the Foxp3 levels were regulated by TIPE2, but not vice versa. Thus, it seemed that TIPE2 was upstream of Foxp3 and this pathway was activated upon Crocetin treatment. Furthermore, the block of this pathway at either TIPE2 or Foxp3 level completely abolished the activation of Treg by Crocetin.
Together, our data suggest that Crocetin may increase Foxp3 through TIPE2 to activate Treg to suppress the severity of asthma, and reveal a previously unrecognized crosstalk between TIPE2 and Foxp3 in the regulation of Treg to affect the severity of asthma, specifically after Crocetin treatment. Thus, our studies may shed light on TIPE2 as a novel therapeutic target for treating allergic asthma.
Disclosure Statement
The authors have declared that no competing interests exist. 
